Prevention of AIDS
Prevention of AIDS
批准号:
7338497
负责人:
BARBARA K FELBER
金额:
$0.0万
依托单位国家:
美国
项目类别:
财政年份:
--
资助国家:
美国
项目状态:
未结题
起止时间:
至
关键词:
中文摘要
点击翻译按钮获取中文摘要
英文摘要
To study prevention of AIDS, we have a long-standing collaboration with George Pavlakis (Human Retrovirus Section, Vaccine Branch), and we have generated efficient DNA expression vectors, which are currently evaluated as vaccines against SIV and HIV. This work is based on the previous recognition that RNA elements (called INS) present within the gag/pol and env coding regions of HIV are responsible for nuclear retention and instability of the transcripts in the absence of Rev, and that these elements can be eliminated by changing the RNA composition without affecting the amino acid sequence. These RNA optimized gag and env expression vectors mediate the development of protective immune responses in vaccinated macaques when used as DNA only as well as DNA prime vaccine modality. We have now shown that that a combination of DNA vaccine vectors producing native and modified antigens are able to induce immune responses able to protect from high viremia in the rhesus macaque/SIVmac251 model. Current studies examine the role of these DNA vaccines as therapeutic modalities. In collaboration with other investigators we have studied immunogenicity of additional HIV and SIV genes either as DNAs or as part of viral vectors. We have shown that these DNAs provide an excellent prime in DNA prime-recombinant Herpes boost studies inducing protective immune responses. We have also shown that combinations of SIV DNA vaccine together with IL-12 or IL-15 as DNA adjuvants improve immunogenicity.Our goal is to dissect correlates of protective immunity, which will allow design of better vaccine strategies. Thus infected macaques, able to control viremia serve as model to study the underlying mechanisms. Among the 'controllers', animals infected with live-attenuated SIV strains provide an important model to study cellular and viral determinants that contribute to disease development and they also provide a unique tool to study mechanisms leading to protective immunity. We study the regulated expression of HIV, which is mediated via the viral Rev protein with the goal to evaluate the role of Rev in pathogenesis. Our discovery of other RNA export mechanisms (mediate via cellular RNA export factors and retrovial RNA export elements CTE, RTE as studied in project 1) provided the key tools to generate HIV and SIV variants that have the Rev/RRE regulatory system replaced. CTE or RTE provide us also with useful tools to achieve efficient expression of HIV and SIV structural protein in simple DNA vectors used as vaccine approaches against AIDS. Importantly, we found that our Rev-independent SIV strains are not pathogenic in rhesus macaques, which demonstrates that the Rev regulation plays an important role for SIV pathogenicity. In a recent long-term follow-up study we showed that such animals show persistent humoral and cellular SIV-specific immune responses, consistent with chronic infection but lack of pathogenicity. Multicolor flow cytometric analysis demonstrated preservation of the Central Memory subset of T-cells in the attenuated SIV-infected animals. This study demonstrates a potent, long-lasting control of the Rev-independent attenuated SIV in macaques. Replacement of the natural regulatory controls of Rev-RRE by the CTE provides a novel approach to lower the virulence of a pathogenic lentivirus. These studies provide critical information about the establishment and maintenance of host immune responses during chronic retroviral infections with distinct pathogenic outcomes. Macaques immunized with attenuated viruses develop persistent humoral and cellular immune responses, able to protect the animals from highly pathogenic SIV challenge. We are in the process to study the underlying mechanism. Therefore, these live-attenuated SIV strains provide us not only with a unique tool to dissect cellular and viral determinants that contribute to AIDS development, but are also useful for studying correlates of protective immunity.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
PATHOGENICITY OF SIVMAC239 VARIANTS IN NEONATAL MACAQUES
-
批准号:7958994
-
项目类别:
-
资助金额:$10.99万
-
财政年份:2009
-
负责人:BARBARA K FELBER
-
依托单位:
PATHOGENICITY OF SIVMAC239 VARIANTS IN NEONATAL MACAQUES
-
批准号:7715569
-
项目类别:
-
资助金额:$16.9万
-
财政年份:2008
-
负责人:BARBARA K FELBER
-
依托单位:
PATHOGENICITY OF SIVMAC239 VARIANTS IN NEONATAL MACAQUES
-
批准号:7562160
-
项目类别:
-
资助金额:$18.16万
-
财政年份:2007
-
负责人:BARBARA K FELBER
-
依托单位:
PATHOGENICITY OF SIVMAC239 VARIANTS IN NEONATAL MACAQUES
-
批准号:7349647
-
项目类别:
-
资助金额:$15.67万
-
财政年份:2006
-
负责人:BARBARA K FELBER
-
依托单位:
PATHOGENICITY OF SIVMAC239 VARIANTS IN NEONATAL MACAQUES
-
批准号:7165446
-
项目类别:
-
资助金额:$20.71万
-
财政年份:2005
-
负责人:BARBARA K FELBER
-
依托单位:
PATHOGENICITY OF SIVMAC239 VARIANTS IN NEONATAL MACAQUES
-
批准号:6971437
-
项目类别:
-
资助金额:$12.23万
-
财政年份:2004
-
负责人:BARBARA K FELBER
-
依托单位:
PATHOGENICITY OF REV INDEPENDENT SIVMAC239 VARIANTS IN NEONATAL MACAQUES
-
批准号:6940445
-
项目类别:
-
资助金额:$16.52万
-
财政年份:2003
-
负责人:BARBARA K FELBER
-
依托单位:
Pathogenicity and immunogenicity of live attenuated SIV
-
批准号:6559234
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:BARBARA K FELBER
-
依托单位:
Pathogenicity and immunogenicity of live attenuated SIV
-
批准号:7052679
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:BARBARA K FELBER
-
依托单位:
Prevention of AIDS
-
批准号:8763086
-
项目类别:
-
资助金额:$216.86万
-
财政年份:--
-
负责人:BARBARA K FELBER
-
依托单位:
Posttranscriptional control of gene expression
-
批准号:8937714
-
项目类别:
-
资助金额:$51.33万
-
财政年份:--
-
负责人:BARBARA K FELBER
-
依托单位:
Posttranscriptional control of gene expression
-
批准号:6763555
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:BARBARA K FELBER
-
依托单位:
Conserved Element DNA Vaccine
-
批准号:10014353
-
项目类别:
-
资助金额:$225.17万
-
财政年份:--
-
负责人:BARBARA K FELBER
-
依托单位:
Prevention of AIDS
-
批准号:7592681
-
项目类别:
-
资助金额:$76.81万
-
财政年份:--
-
负责人:BARBARA K FELBER
-
依托单位:
COVID-19 vaccine development research
-
批准号:10262556
-
项目类别:
-
资助金额:$93.35万
-
财政年份:--
-
负责人:BARBARA K FELBER
-
依托单位:
Prevention of AIDS
-
批准号:10262077
-
项目类别:
-
资助金额:$186.69万
-
财政年份:--
-
负责人:BARBARA K FELBER
-
依托单位:
Immunotherapeutic Interventions of AIDS and Cancer
-
批准号:9556267
-
项目类别:
-
资助金额:$106.25万
-
财政年份:--
-
负责人:BARBARA K FELBER
-
依托单位:
Prevention of AIDS
-
批准号:7733015
-
项目类别:
-
资助金额:$241.74万
-
财政年份:--
-
负责人:BARBARA K FELBER
-
依托单位:
Posttranscriptional control of gene expression
-
批准号:7733004
-
项目类别:
-
资助金额:$103.6万
-
财政年份:--
-
负责人:BARBARA K FELBER
-
依托单位:
Posttranscriptional control of gene expression
-
批准号:7291715
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:BARBARA K FELBER
-
依托单位:
国内基金
海外基金
登录
查看更多内容
基于病人旅程地图的HIV/AIDS患者双轨调适策略的混合性研究
-
批准号:2026JJ81431
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:夏友
-
依托单位:
基于潜变量增长混合模型的HIV/AIDS患者症状负担发展轨迹研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:胡亚丽
-
依托单位:
基于RET理论模型下的曼陀罗彩绘疗法在老年HIV/AIDS患者中的心理干预研究
-
批准号:2025JJ80476
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:余一知
-
依托单位:
IL-33/NF-κB通路在臭氧暴露致HIV/AIDS患者免疫损伤中的调控机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:
-
依托单位:
IL-6与VV-ECMO治疗AIDS合并重度ARDS患者预后的相关性探索
-
批准号:2025JJ80496
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:黄康
-
依托单位:
HIV/AIDS患者症状群轨迹、影响因素及其对机会性感染的预测作用
-
批准号:
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2024
-
负责人:陆俊雯
-
依托单位:
基于社会心理行为表型组的HIV/AIDS患者高危性行为精准干预策略研究
-
批准号:2023JJ40787
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2023
-
负责人:肖雪玲
-
依托单位:
SIV猕猴感染模型中共生病毒组的演化特征及其参与AIDS进展的机制研究
-
批准号:32370153
-
项目类别:面上项目
-
资助金额:50万元
-
批准年份:2023
-
负责人:李龑鹏
-
依托单位:
求助者中心疗法在HIV/AIDS合并外科疾病手术治疗患者中的应用研究
-
批准号:2023JJ60392
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2023
-
负责人:夏友
-
依托单位:
边境流动人群HIV/AIDS感染的非恒等动力系统复杂网络构建及防控策略优化的研究
-
批准号:72274086
-
项目类别:面上项目
-
资助金额:45万元
-
批准年份:2022
-
负责人:李静
-
依托单位: